Sophia Genetics Stock Up 9% to $5.75 After Q4 and FY26 Guidance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Should l Buy SOPH?
Sophia Genetics up 9% at $5.75 after Q4 and FY26 guidance
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SOPH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SOPH
Wall Street analysts forecast SOPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SOPH is 7.00 USD with a low forecast of 7.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.600
Low
7.00
Averages
7.00
High
7.00
Current: 4.600
Low
7.00
Averages
7.00
High
7.00
About SOPH
SOPHiA GENETICS SA is a Switzerland-based company primarily engaged in the healthcare technology industry. The Company’s key product is SOPHiA DDM, which is a cloud-native software-as-a-service (SaaS) platform. The platform analyses multimodal data, including genomics, radiomics, clinical, biological, and digital pathology data, to generate actionable insights for patients with cancer or rare diseases, bringing the power of data-driven medicine to patients across the globe. Additionally, the Company aids BioPharma partners with artificial-intelligence-powered drug discovery, development, and deployment. The Company has offices in Switzerland, France, and the United States and operates worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SOPHiA GENETICS Projects 20%-22% Revenue Growth in 2026 and Appoints New CEO
- 2025 Financial Performance: SOPHiA GENETICS anticipates a revenue growth of 20%-22% for Q4 and the full year 2025, indicating strong performance in the AI-driven precision medicine sector and laying a solid foundation for future growth.
- Management Transition: The company announced that Ross Muken will succeed Jurgi Camblong as CEO on July 1, 2026, with Camblong transitioning to Executive Chairman, ensuring continuity and stability in the company's strategic direction.
- Market Opportunities: SOPHiA GENETICS plans to leverage its leading liquid biopsy application MSK-ACCESS® and potential opportunities in the U.S. market to further drive business growth in 2026, demonstrating the company's keen insight into market demands.
- Strategic Investment: During Muken's tenure, he successfully transformed the commercial organization and accelerated sales processes, and he is expected to continue leveraging his extensive experience to enhance the company's global impact and market share.
See More
SOPHiA GENETICS Reports Strong Q4 2025 Performance, Projects 20-22% Revenue Growth for 2026
- Strong 2025 Performance: SOPHiA GENETICS reported robust Q4 results in 2025, exceeding new business booking targets and laying the groundwork for future growth, with projected revenue growth of 20-22% in 2026, highlighting the company's sustained leadership in precision medicine.
- Executive Transition Plan: The company announced that Ross Muken will succeed co-founder Jurgi Camblong as CEO on July 1, 2026, while Camblong transitions to Executive Chairman, ensuring continuity and stability in the company's strategic direction.
- Market Opportunities and Growth Catalysts: SOPHiA GENETICS aims to leverage its leading Liquid Biopsy application MSK-ACCESS® and valuable opportunities in the U.S. market to reinvigorate its BioPharma business, which is expected to significantly enhance operational leverage and financial position.
- Strategic Leadership Adjustments: Kevin Puylaert has been appointed Chief Sales Officer, tasked with driving sales growth in the EMEA region, further solidifying the company's competitive edge in the global market.
See More
SOPHiA GENETICS Reports Strong Q4 2025 Performance, Expects 20-22% Revenue Growth in 2026
- Strong 2025 Performance: SOPHiA GENETICS reported robust Q4 performance in 2025, exceeding new business bookings targets and laying the groundwork for future growth, with a projected revenue increase of 20-22% in 2026, highlighting the company's strong potential in precision medicine.
- Executive Transition Plan: The company announced the promotion of Ross Muken to CEO, succeeding co-founder Jurgi Camblong, aiming to ensure continuity in the company's long-term strategic direction and development.
- Market Opportunities: SOPHiA GENETICS plans to drive growth in 2026 through its leading Liquid Biopsy application MSK-ACCESS® and opportunities in the U.S. market, which is expected to further enhance its position in the biopharma sector.
- Leadership Stability: Jurgi Camblong will transition to Executive Chairman, focusing on strategic innovation to ensure the company's global impact continues to expand, reflecting the company's confidence and commitment to future growth.
See More
SOPHiA GENETICS Projects 20-22% Revenue Growth for 2026
- Strong Financial Performance: SOPHiA GENETICS reported robust results for Q4 2025, projecting a revenue growth of 20-22% for 2026, indicating the company's sustained growth potential and strong market demand in the precision medicine sector.
- Leadership Transition: Ross Muken will take over as CEO on July 1, 2026, succeeding co-founder Jurgi Camblong, who will become Executive Chairman, ensuring continuity and stability in the company's strategic direction.
- Market Opportunities: The company plans to leverage new products like MSK-ACCESS® and opportunities in the U.S. market to further revive its BioPharma business, thereby enhancing its competitiveness in the global precision medicine market.
- Strategic Investment: Muken, who has held key positions over the past five years, successfully drove the company's business transformation and is expected to continue leveraging his extensive industry experience to expand SOPHiA GENETICS' international impact, supporting the company in its next growth phase.
See More
SOPHiA GENETICS Reports Strong Q4 2025 Performance, Projects 20%-22% Growth for 2026
- Strong 2025 Performance: SOPHiA GENETICS reported significant growth in 2025, with projected revenue growth of 20%-22% for 2026, establishing a solid foundation for the company's future expansion.
- Leadership Transition: The company announced that Ross Muken will succeed Jurgi Camblong as CEO on July 1, 2026, with Camblong transitioning to Executive Chairman, ensuring continuity and stability in strategic direction.
- Market Opportunities: SOPHiA GENETICS will focus on developing its MSK-ACCESS® liquid biopsy application and seek new opportunities in the U.S. market while revitalizing its biopharma business, which is expected to further drive revenue growth.
- Strategic Investment: The company plans to enhance its global influence in the healthcare market through technological innovation and market expansion, particularly in the field of data-driven precision medicine, driving long-term growth.
See More
SOPHiA GENETICS Partners with MD Anderson to Accelerate Cancer Data Analysis
- Strategic Collaboration: SOPHiA GENETICS has partnered with MD Anderson Cancer Center to integrate AI analytics with clinical expertise, aiming to accelerate data-driven cancer care and enhance the clinical application of diagnostic results.
- R&D Program Launch: The collaboration will initiate a series of R&D programs to co-develop a next-generation sequencing oncology test based on the SOPHiA DDM™ platform, designed to translate complex data into actionable clinical insights with greater speed and scale.
- Bioinformatics Pipeline Development: MD Anderson researchers will leverage SOPHiA's AI technologies to create bioinformatics pipelines that enable rapid interpretation of complex RNA sequencing data, thereby guiding diagnosis and treatment for cancer patients and improving clinical decision-making efficiency.
- Advancing Scientific Discovery: This collaboration will not only propel advancements in cancer research but also enhance real-time characterization of tumor evolution, improve the reliability of genomic testing, and facilitate the development of personalized treatment plans for patients.
See More
SOPHiA GENETICS Projects 20%-22% Revenue Growth in 2026 and Appoints New CEO
- 2025 Financial Performance: SOPHiA GENETICS anticipates a revenue growth of 20%-22% for Q4 and the full year 2025, indicating strong performance in the AI-driven precision medicine sector and laying a solid foundation for future growth.
- Management Transition: The company announced that Ross Muken will succeed Jurgi Camblong as CEO on July 1, 2026, with Camblong transitioning to Executive Chairman, ensuring continuity and stability in the company's strategic direction.
- Market Opportunities: SOPHiA GENETICS plans to leverage its leading liquid biopsy application MSK-ACCESS® and potential opportunities in the U.S. market to further drive business growth in 2026, demonstrating the company's keen insight into market demands.
- Strategic Investment: During Muken's tenure, he successfully transformed the commercial organization and accelerated sales processes, and he is expected to continue leveraging his extensive experience to enhance the company's global impact and market share.
See More
SOPHiA GENETICS Reports Strong Q4 2025 Performance, Projects 20-22% Revenue Growth for 2026
- Strong 2025 Performance: SOPHiA GENETICS reported robust Q4 results in 2025, exceeding new business booking targets and laying the groundwork for future growth, with projected revenue growth of 20-22% in 2026, highlighting the company's sustained leadership in precision medicine.
- Executive Transition Plan: The company announced that Ross Muken will succeed co-founder Jurgi Camblong as CEO on July 1, 2026, while Camblong transitions to Executive Chairman, ensuring continuity and stability in the company's strategic direction.
- Market Opportunities and Growth Catalysts: SOPHiA GENETICS aims to leverage its leading Liquid Biopsy application MSK-ACCESS® and valuable opportunities in the U.S. market to reinvigorate its BioPharma business, which is expected to significantly enhance operational leverage and financial position.
- Strategic Leadership Adjustments: Kevin Puylaert has been appointed Chief Sales Officer, tasked with driving sales growth in the EMEA region, further solidifying the company's competitive edge in the global market.
See More
SOPHiA GENETICS Reports Strong Q4 2025 Performance, Expects 20-22% Revenue Growth in 2026
- Strong 2025 Performance: SOPHiA GENETICS reported robust Q4 performance in 2025, exceeding new business bookings targets and laying the groundwork for future growth, with a projected revenue increase of 20-22% in 2026, highlighting the company's strong potential in precision medicine.
- Executive Transition Plan: The company announced the promotion of Ross Muken to CEO, succeeding co-founder Jurgi Camblong, aiming to ensure continuity in the company's long-term strategic direction and development.
- Market Opportunities: SOPHiA GENETICS plans to drive growth in 2026 through its leading Liquid Biopsy application MSK-ACCESS® and opportunities in the U.S. market, which is expected to further enhance its position in the biopharma sector.
- Leadership Stability: Jurgi Camblong will transition to Executive Chairman, focusing on strategic innovation to ensure the company's global impact continues to expand, reflecting the company's confidence and commitment to future growth.
See More
SOPHiA GENETICS Projects 20-22% Revenue Growth for 2026
- Strong Financial Performance: SOPHiA GENETICS reported robust results for Q4 2025, projecting a revenue growth of 20-22% for 2026, indicating the company's sustained growth potential and strong market demand in the precision medicine sector.
- Leadership Transition: Ross Muken will take over as CEO on July 1, 2026, succeeding co-founder Jurgi Camblong, who will become Executive Chairman, ensuring continuity and stability in the company's strategic direction.
- Market Opportunities: The company plans to leverage new products like MSK-ACCESS® and opportunities in the U.S. market to further revive its BioPharma business, thereby enhancing its competitiveness in the global precision medicine market.
- Strategic Investment: Muken, who has held key positions over the past five years, successfully drove the company's business transformation and is expected to continue leveraging his extensive industry experience to expand SOPHiA GENETICS' international impact, supporting the company in its next growth phase.
See More
SOPHiA GENETICS Reports Strong Q4 2025 Performance, Projects 20%-22% Growth for 2026
- Strong 2025 Performance: SOPHiA GENETICS reported significant growth in 2025, with projected revenue growth of 20%-22% for 2026, establishing a solid foundation for the company's future expansion.
- Leadership Transition: The company announced that Ross Muken will succeed Jurgi Camblong as CEO on July 1, 2026, with Camblong transitioning to Executive Chairman, ensuring continuity and stability in strategic direction.
- Market Opportunities: SOPHiA GENETICS will focus on developing its MSK-ACCESS® liquid biopsy application and seek new opportunities in the U.S. market while revitalizing its biopharma business, which is expected to further drive revenue growth.
- Strategic Investment: The company plans to enhance its global influence in the healthcare market through technological innovation and market expansion, particularly in the field of data-driven precision medicine, driving long-term growth.
See More
SOPHiA GENETICS Partners with MD Anderson to Accelerate Cancer Data Analysis
- Strategic Collaboration: SOPHiA GENETICS has partnered with MD Anderson Cancer Center to integrate AI analytics with clinical expertise, aiming to accelerate data-driven cancer care and enhance the clinical application of diagnostic results.
- R&D Program Launch: The collaboration will initiate a series of R&D programs to co-develop a next-generation sequencing oncology test based on the SOPHiA DDM™ platform, designed to translate complex data into actionable clinical insights with greater speed and scale.
- Bioinformatics Pipeline Development: MD Anderson researchers will leverage SOPHiA's AI technologies to create bioinformatics pipelines that enable rapid interpretation of complex RNA sequencing data, thereby guiding diagnosis and treatment for cancer patients and improving clinical decision-making efficiency.
- Advancing Scientific Discovery: This collaboration will not only propel advancements in cancer research but also enhance real-time characterization of tumor evolution, improve the reliability of genomic testing, and facilitate the development of personalized treatment plans for patients.
See More
